Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9396527 | 0.82 | ELANE (0.49) | CASP3 | |
| SCHEMBL9396521 | 0.82 | ELANE (0.49) | CASP3 | |
| SCHEMBL21809386 | 0.80 | PIK3CG (0.50) | MDM4TP53MDM2 | |
| SCHEMBL21809388 | 0.80 | PIK3CG (0.50) | MDM4TP53MDM2 | |
| SCHEMBL16822334 | 0.79 | ELANE (0.43) | — | |
| SCHEMBL9396722 | 0.78 | ELANE (0.44) | CASP3 | |
| SCHEMBL9396718 | 0.78 | ELANE (0.44) | CASP3 | |
| SCHEMBL801052 | 0.70 | CASP3 (0.43) | CASP3MDM4TP53MDM2EPHX2 | |
| SCHEMBL15597727 | 0.69 | ALDH1A1 (0.39) | TP53KMT2A | |
| SCHEMBL6795717 | 0.68 | KMT2A (0.54) | CASP3MDM4TP53EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870650-B2 | Process for the preparation of amorphous idelalisib | NATCO PHARMA LIMITED (IN) | 2020-12-22 | — | — | US | disclosed |
| US-20200095249-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB | NATCO PHARMA LIMITED (IN) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095249-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB | IDE, PDE8B, PCSK9 | CXCR2 2458/4885CASP3 3245/4885MDM4 1621/4885 |
| US-10870650-B2 | Process for the preparation of amorphous idelalisib | IDE, PDE8B, PCSK9 | CXCR2 2458/4885CASP3 3245/4885MDM4 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.